

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACTAVIS, INC., ACTAVIS LABORATORIES FL, INC., ACTAVIS PHARMA,
INC., AMNEAL PHARMACEUTICALS, LLC, AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC, AUROBINDO PHARMA LTD.,
AUROBINDO PHARMA USA, INC., BRECKENRIDGE PHARMACEUTICAL,
INC., VENNOOT PHARMACEUTICALS, LLC, SANDOZ INC., SUN
PHARMA GLOBAL FZE, and SUN PHARMACEUTICAL INDUSTRIES, LTD.,
Petitioner

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner

Case IPR2014-01126
Patent RE38,551

**PATENT OWNER PRELIMINARY RESPONSE
PURSUANT TO 37 C.F.R. § 42.107**

LIST OF EXHIBITS

Exhibit	Description
2001	Richard H. Mattson, <i>Efficacy and Adverse Effects of Established and New Antiepileptic Drugs</i> , 36 (Suppl. 2) <i>Epilepsia</i> S13-S26 (1995).
2002	FDA Approved Labeling Text dated August 27, 2012 for FELBATOL [®] (felbamate) , <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf (last visited Oct. 23, 2014).
2003	Robert Thornton Morrison & Robert Neilson Boyd, <i>Organic Chemistry</i> 120-133 (3d ed. 1973).
2004	Jerry March, <i>Advanced Organic Chemistry</i> 16-18 (3d ed. 1985).
2005	Richard H. Mattson, <i>Drug treatment of uncontrolled seizures, in Surgical Treatment of Epilepsy</i> 29-35 (William H. Theodore ed., 1992).
2006	John M. Pellock, <i>Standard Approach to Antiepileptic Drug Treatment in the United States</i> 35 (Suppl. 4) <i>Epilepsia</i> S11-S18 (1994).
2007	Approval Listing dated December 27, 1994 for lamotrigine, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020241&TABLE1=OB_Rx (last visited Oct. 23, 2014).
2008	The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915, 998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330, 1654 (Susan Budavari et al. eds., 12th ed. 1996).
2009	Approval Listing dated August 5, 1996 for fosphenytoin sodium, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020450&TABLE1=OB_Rx (last visited Oct. 23, 2014).

Exhibit	Description
2010	FDA Approved Labeling Text dated January 2014 for CEREBYX [®] (fosphenytoin sodium injection) , <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020450s023lbl.pdf (last visited Oct. 23, 2014).
2011	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Beclamide, http://chem.sis.nlm.nih.gov/chemidplus/rn/501-68-8 (last visited Oct. 23, 2014).
2012	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Phenacemide, http://chem.sis.nlm.nih.gov/chemidplus/rn/63-98-9 (last visited Oct. 23, 2014).
2013	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Valproic acid, http://chem.sis.nlm.nih.gov/chemidplus/rn/99-66-1 (last visited Oct. 23, 2014).
2014	Rogawski & Porter, <i>Antiepileptic Drugs: Pharmacological Mechanisms and Clinical Efficacy with Consideration of Promising Developmental Stage Compounds</i> , 42(3) <i>Pharmacol. Rev.</i> 223-86 (1990).
2015	Bialer <i>et al.</i> , <i>Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)</i> , 51 <i>Epilepsy Res.</i> 31-71 (2002).

TABLE OF CONTENTS

	Page(s)
I. Introduction.....	1
II. The Development of the Inventions and the ‘551 Patent.....	5
III. Level of Ordinary Skill in the Art	10
IV. Claim Construction Under “Broadest Reasonable Interpretation”	11
A. Petitioner’s Implicit Claim Construction of “Compound in the R Configuration” is Flawed.....	11
B. Therapeutic Composition	13
V. Petitioner Has Not Shown a Reasonable Likelihood That at Least One Claim of the ‘551 Patent Is Unpatentable.....	15
A. Petitioner Has Failed to Show That the ‘301 Patent Anticipates Any Claim	15
1. Claims 2 and 9.....	21
2. Claim 10.....	22
3. Claims 11-13	25
B. Petitioner Has Failed to Show That the LeGall Thesis Is Prior Art Under 35 U.S.C. § 102.....	27
C. Petitioner Has Failed to Show That the LeGall Thesis Anticipates Any Claim	30
1. Claims 2 and 9.....	32
2. Claim 10.....	34
3. Claims 11-13	36
D. Petitioner Has Failed to Show That Claims 1-13 are Unpatentable Over the LeGall Thesis in View of the ‘729 Patent and “Other Prior Art”	37

- 1. Violating PTAB Regulations, The Petition Fails to Demonstrate a Reasonable Likelihood of Prevailing 37
- 2. The Petition Cherry-Picks From a Multitude of Compounds, Contravening Proper Lead Compound Analysis..... 41
- 3. Claims 10 and 11-13 53
- VI. Objective Indicia Confirm That Petitioner Has Not Demonstrated A Reasonable Likelihood That At Least One Claim of the ‘551 Patent Is Obvious..... 56
- VII. Conclusion 59

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.